A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids

Citations Over TimeTop 1% of 2023 papers

Abstract

The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%-38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.

Related Papers

• → Time-dependent diffusion MRI-based microstructural mapping for differentiating high-grade serous ovarian cancer from serous borderline ovarian tumor(2024)15 cited
• → Diagnosis shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study(2020)1 cited
• → Selective activation of Notch3 in high-grade serous ovarian cancer(2014)
• Expression of CLN3 Gene in Ovarian Serous Cancer(2008)
• Expression and diagnostic value of HE4 level in early serous ovarian(2013)